Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication.


The emergence of the pandemic 2009 H1N1 influenza virus has become a world-wide health concern. As drug resistance appears, a new generation of therapeutic strategies will be required. Here, we introduce a nanotechnology approach for the therapy of pan-demic and seasonal influenza virus infections. This approach uses gold nanorods (GNRs) to deliver an innate immune activator, pro-ducing a localized therapeutic response. We demonstrated the utility of a biocompatible gold nanorod, GNR-5'PPP-ssRNA nanoplex, as an antiviral strategy against type A influenza virus. In human respiratory bronchial epithelial cells, this nanoplex activated the retinoic acid-inducible gene I (RIG-I) pathogen recognition pathway, resulting in increased expression of IFN-beta and other IFN-stimulated genes (ISGs) (e.g., PKR, MDA5, IRF1, IRF7, and MX1). This increase in type I IFN and ISGs resulted in a decrease in the replication of H1N1 influenza viruses. These findings suggest that further evaluation of biocompatible nanoplexes as unique antivirals for treatment of seasonal and pandemic influenza viruses is warranted.

DOI: 10.1073/pnas.0914561107
Citations per Year

61 Citations

Semantic Scholar estimates that this publication has 61 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Chakravarthy2010GoldND, title={Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication.}, author={Krishnan V Chakravarthy and Adela C Bonoiu and William G. Davis and Priya Ranjan and Hong Ding and Rui Hu and John Bradford Bowzard and Earl J. Bergey and Jacqueline M . Katz and Paul Knight and Suryaprakash Sambhara and Paras N. Prasad}, journal={Proceedings of the National Academy of Sciences of the United States of America}, year={2010}, volume={107 22}, pages={10172-7} }